ATE481409T1 - Thiazolopyramidin/pyridinharnstoffderivate als antagonisten am adenosin-a2b-rezeptor - Google Patents

Thiazolopyramidin/pyridinharnstoffderivate als antagonisten am adenosin-a2b-rezeptor

Info

Publication number
ATE481409T1
ATE481409T1 AT07728869T AT07728869T ATE481409T1 AT E481409 T1 ATE481409 T1 AT E481409T1 AT 07728869 T AT07728869 T AT 07728869T AT 07728869 T AT07728869 T AT 07728869T AT E481409 T1 ATE481409 T1 AT E481409T1
Authority
AT
Austria
Prior art keywords
thiazolopyramidine
adenosine
antagonists
receptor
urea derivatives
Prior art date
Application number
AT07728869T
Other languages
English (en)
Inventor
John A Brinkman
Adrian Wai-Hing Cheung
Fariborz Firooznia
Kevin Richard Guertin
Nicholas Marcopulos
Lida Qi
Jagdish Kumar Racha
Ramakanth Sarabu
Jenny Tan
Jefferson Wright Tilley
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE481409T1 publication Critical patent/ATE481409T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D521/00—Heterocyclic compounds containing unspecified hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT07728869T 2006-05-18 2007-05-08 Thiazolopyramidin/pyridinharnstoffderivate als antagonisten am adenosin-a2b-rezeptor ATE481409T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80148106P 2006-05-18 2006-05-18
PCT/EP2007/054416 WO2007134958A1 (en) 2006-05-18 2007-05-08 Thiazolo-pyramidine / pyridine urea derivatives as adenosine a2b receptor antagonists

Publications (1)

Publication Number Publication Date
ATE481409T1 true ATE481409T1 (de) 2010-10-15

Family

ID=38308768

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07728869T ATE481409T1 (de) 2006-05-18 2007-05-08 Thiazolopyramidin/pyridinharnstoffderivate als antagonisten am adenosin-a2b-rezeptor

Country Status (17)

Country Link
US (1) US7947692B2 (de)
EP (1) EP2027132B1 (de)
JP (1) JP5026511B2 (de)
KR (1) KR101077295B1 (de)
CN (1) CN101448844B (de)
AR (1) AR060957A1 (de)
AT (1) ATE481409T1 (de)
AU (1) AU2007253485B2 (de)
BR (1) BRPI0712516A2 (de)
CA (1) CA2651769C (de)
CL (1) CL2007001380A1 (de)
DE (1) DE602007009221D1 (de)
ES (1) ES2350013T3 (de)
IL (1) IL195006A0 (de)
MX (1) MX2008014690A (de)
TW (1) TW200813073A (de)
WO (1) WO2007134958A1 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ590148A (en) 2004-12-30 2012-04-27 Janssen Pharmaceutica Nv Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase
AU2008263166A1 (en) * 2007-05-25 2008-12-18 Janssen Pharmaceutica N.V. Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
US8455520B2 (en) 2007-07-17 2013-06-04 Merck Sharp & Dohme Corp. Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2009078999A1 (en) * 2007-12-17 2009-06-25 Janssen Pharmaceutica N.V. Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of trpv1
WO2009097995A1 (de) * 2008-02-07 2009-08-13 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2010068452A1 (en) * 2008-11-25 2010-06-17 Janssen Pharmaceutica Nv Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
US8461159B2 (en) 2008-11-25 2013-06-11 Jannsen Pharmaceutica BV Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
WO2010103130A2 (en) * 2009-03-13 2010-09-16 Katholieke Universiteit Leuven, K.U.Leuven R&D Novel bicyclic heterocycles
US20120083476A1 (en) 2009-06-05 2012-04-05 Janssen Pharmaceutica Nv Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
US8901111B2 (en) 2009-06-05 2014-12-02 Janssen Pharmaceutica Nv Aryl-substituted heterocyclic urea modulators of fatty acid amide hydrolase
SG178102A1 (en) * 2009-07-24 2012-03-29 Univ Vanderbilt Isoform selective phospholipase d inhibitors
EP2518064A1 (de) * 2009-12-25 2012-10-31 Mochida Pharmaceutical Co., Ltd. Neues arylharnstoffderivat
UA108233C2 (uk) 2010-05-03 2015-04-10 Модулятори активності гідролази амідів жирних кислот
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
AU2011329233A1 (en) 2010-11-15 2013-05-23 Abbvie Deutschland Gmbh & Co Kg NAMPT and ROCK inhibitors
MX2013005479A (es) * 2010-11-15 2013-06-12 Abbvie Inc Inhibidores de nampt.
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2567959B1 (de) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamid-derivate als kinaseinhibitoren
DE102011083283A1 (de) * 2011-09-23 2013-03-28 Beiersdorf Ag Heteroalkylamidothiazole, deren kosmetische oder dermatologische Verwendung sowie kosmetische oder dermatologische Zubereitungen mit einem Gehalt an solchen Heteroalkylamidothiazolen
WO2013049773A1 (en) 2011-09-30 2013-04-04 Vanderbilt University Antiviral therapies with phospholipase d inhibitors
EA201391552A1 (ru) * 2012-03-01 2014-12-30 Общество с ограниченной ответственностью "Метаген" 2-нитрогетерилтиоцианаты для лечения грибковых инфекций, фармацевтическая композиция и их применение
RU2504541C1 (ru) * 2012-12-26 2014-01-20 Общество с ограниченной ответственностью "Метаген" 2-нитрогетерилтиоцианаты для лечения грибковых инфекций, фармацевтическая композиция для местного применения
RU2475481C1 (ru) * 2012-03-01 2013-02-20 Общество с ограниченной ответственностью "Метаген" 2-нитрогетерилтиоцианаты для лечения грибковых инфекций, фармацевтическая композиция и их применение
US9938291B2 (en) 2013-03-14 2018-04-10 The Trustess Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
WO2014152018A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York Octahydrocyclopentapyrroles, their preparation and use
EP3495357B1 (de) 2013-03-14 2021-05-05 The Trustees of Columbia University in the City of New York 4-phenylpiperidine, deren herstellung und verwendung
US9944644B2 (en) 2013-03-14 2018-04-17 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles their preparation and use
KR20160065957A (ko) * 2013-10-07 2016-06-09 바이엘 파마 악티엔게젤샤프트 시클릭 티에노우라실-카르복스아미드 및 그의 용도
SG11201608943VA (en) 2014-04-30 2016-11-29 Univ Columbia Substituted 4-phenylpiperidines, their preparaiton and use
LT3483164T (lt) 2017-03-20 2020-05-11 Forma Therapeutics, Inc. Pirolpirolo kompozicijos kaip piruvato kinazės (pkr) aktyvatoriai
PT3661941T (pt) * 2017-08-01 2023-03-16 Merck Patent Gmbh Derivados tiazolopiridina como antagonistas do recetor de adenosina
EP3853206B1 (de) 2018-09-19 2024-04-10 Novo Nordisk Health Care AG Behandlung von sichelzellanämie mit einer pyruvatkinase-r-aktivierenden verbindung
EP3852791B1 (de) 2018-09-19 2024-07-03 Novo Nordisk Health Care AG Aktivierung von pyruvatkinase r
MX2021008094A (es) 2019-01-11 2021-09-21 Omeros Corp Metodos y composiciones para el tratamiento del cancer.
HRP20251148T1 (hr) 2019-09-19 2025-11-21 Novo Nordisk Health Care Ag Pripravci koji aktiviraju piruvat-kinazu r (pkr)
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
EP4351640A1 (de) * 2021-06-07 2024-04-17 Ares Trading S.A. Kombinationsbehandlung von krebs
CN114591327B (zh) * 2022-03-25 2023-02-07 河南大学 吲哚啉哌啶脲类trpv1拮抗和mor激动双靶点药物及制备方法和应用
JP2025512384A (ja) 2022-04-13 2025-04-17 ギリアード サイエンシーズ， インコーポレイテッド Ｔｒｏｐ－２発現がんを治療するための併用療法
UY40605A (es) * 2023-01-17 2024-08-15 Septerna Inc Compuestos, composiciones y métodos de uso para tratar el hipoparatiroidismo y la osteoporosis
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2026019756A1 (en) * 2024-07-16 2026-01-22 Septerna, Inc. Bicyclic heteroaromatic agonists of the parathyroid hormone 1 receptor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6060481A (en) * 1998-05-28 2000-05-09 The Penn State Research Foundation Method for improving insulin sensitivity using an adenosine receptor antagonist
AU2001281817B2 (en) * 2000-06-21 2005-11-24 F. Hoffmann-La Roche Ag Benzothiazole derivatives
US6713499B2 (en) 2001-12-12 2004-03-30 Hoffman-La Roche Inc. 7-Amino-benzothiazole derivatives
EP1388341A1 (de) 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Substituierte Acylamino heteroaromatische Verbindungen und ihre Verwendung als Arztneimittel
RU2006112847A (ru) * 2003-09-19 2007-11-10 Ф. Хоффманн-Ля Рош Аг (Ch) Производные тиазолопиридина в качестве лигандов аденозинового рецептора
GB0401336D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
ES2241496B1 (es) * 2004-04-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridina.
BRPI0514099A (pt) * 2004-08-05 2008-05-27 Hoffmann La Roche composições farmacêuticas, compostos, processo para a sua manufatura, método para o tratamento terapêutico e/ou profilático de enfermidades e utilização dos compostos

Also Published As

Publication number Publication date
TW200813073A (en) 2008-03-16
AU2007253485A1 (en) 2007-11-29
JP2009537473A (ja) 2009-10-29
CA2651769A1 (en) 2007-11-29
AR060957A1 (es) 2008-07-23
MX2008014690A (es) 2008-11-27
CN101448844B (zh) 2012-07-25
US7947692B2 (en) 2011-05-24
CA2651769C (en) 2013-12-17
JP5026511B2 (ja) 2012-09-12
AU2007253485B2 (en) 2010-07-08
IL195006A0 (en) 2009-08-03
CN101448844A (zh) 2009-06-03
CL2007001380A1 (es) 2008-01-04
ES2350013T3 (es) 2011-01-14
EP2027132B1 (de) 2010-09-15
KR101077295B1 (ko) 2011-10-26
US20070270433A1 (en) 2007-11-22
KR20080111141A (ko) 2008-12-22
DE602007009221D1 (de) 2010-10-28
WO2007134958A1 (en) 2007-11-29
EP2027132A1 (de) 2009-02-25
BRPI0712516A2 (pt) 2016-08-23

Similar Documents

Publication Publication Date Title
ATE481409T1 (de) Thiazolopyramidin/pyridinharnstoffderivate als antagonisten am adenosin-a2b-rezeptor
ATE481404T1 (de) Adenosinderivate als agonisten am a2a-rezeptor
ZA200802588B (en) Imidazopyridine derivatives as A2B adenosine receptor antagonists
ATE502040T1 (de) Bisadenosinverbindungen als adenosin-a2a- rezeptoragonisten
ATE505467T1 (de) 2-aza-bicycloä3.1.0ühexanderivate als orexin- rezeptorantagonisten
IL188725A0 (en) Pyrazine derivatives useful as adenosine receptor antagonists
BR112012024870A2 (pt) derivados de 4-aminopirimidina e seus antagonistas do receptor a2a de adenosina
ZA200808191B (en) Pyridine and pyrimidine derivatives as MGLUR2 antagonists
ZA200902187B (en) 8-Ethinylxanthine derivatives as selective A2A receptor antagonists
IL178396A0 (en) Condensed pyridine derivatives useful as a28 adenosine receptor antagonists
IL201234A0 (en) Adenosine a2a receptor antagonists
BRPI0810202A2 (pt) Derivados de piridina
ATE461932T1 (de) Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors
ES2465673T9 (es) Derivados de pirimidina
DK2081951T3 (da) Progesteron-receptorantagonister
ATE540942T1 (de) Imidazolderivate als ccr2-rezeptor-antagonisten
DE602007010456D1 (de) Phenyl-pyrazol-derivate als nicht-steroide glucocorticoid-rezeptorliganden
EP2032797A4 (de) A2b-adenosinrezeptorantagonisten
ATE493400T1 (de) Pyridin- und pyrimidinderivate als mglur2- antagonisten
DE602007008831D1 (de) Cyclohexyl-sulfonamid-derivate mit h3-rezeptoraktivität
ATE454377T1 (de) 2-phenyl-6-aminocarbonylpyrimidinderivate und ihre verwendung als antagonisten am p2y12- rezeptor
ATE414085T1 (de) Purinderivate als a2a-rezeptoragonisten
BRPI0811094A2 (pt) Derivados de heteroarilamida pirimidona
ATE502016T1 (de) Triazolo-ä1,5-aü-chinoline als adenosin-a3- rezeptorliganden
ATE538123T1 (de) 2-heteroarylpyrazoloä4,3-eü-1, 2, 4-triazolo-ä1,5-cü-pyrimidine als antagonisten des adenosin-a2a- rezeptors

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2027132

Country of ref document: EP